Lexicon Pharmaceuticals LXRX Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies

PopularBPOP

$2M—

CBIZCBZ

$125K+150%

HTF

Heartflow, Inc. Common StockHTFL

$400K-90.5%

John Wiley & Sons, Inc.WLYB

-$17.5M-191%

REX American ResourcesREX

$17K—

First BanCorpFBP

-$4.28M—

Questions, answered.

What is Lexicon Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount?

Lexicon Pharmaceuticals (LXRX) reported valuation allowance, deferred tax asset, increase (decrease), amount of $2.53M in Q4 2025.

How has Lexicon Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?

Lexicon Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount decreased by 67.2% year-over-year, from $7.7M to $2.53M.

What is the long-term trend for Lexicon Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount?

Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount has grown at a -12.5% compound annual growth rate (CAGR), from $17.2M to $10.1M.

What does valuation allowance, deferred tax asset, increase (decrease), amount mean?

This metric tracks the net change in the valuation allowance established against deferred tax assets, reflecting management's assessment of the likelihood that these assets will be realized. An increase in the allowance suggests management has become less confident in the company's ability to generate sufficient future taxable income to utilize these tax benefits. It is a key indicator of the company's long-term profitability outlook from a tax perspective.